🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 15117K103
- Market Cap
- Large Cap
- IPO
- 3/24/2015 · $41.50/share
- ADR Ratio
- 1:1
Business: Cellectis S.A. is a pioneering gene-editing company, employing its core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology. The Company's product candidates, based on gene-edited T-cells that express chimeric antigen receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers.
Company Contact
- CEO
- André Choulika
- CFO
- Arthur Stril
- Headquarters
- 430 East 29th Street, New York, NY 10016
- Phone
- 347-809-5980
- Investor Relations
- Simon Harnest · 646-385-9008 · simon.harnest@cellectis.com